Yumanity Therapeutics Inc YTX-7739 Topline Data Discussion Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Yumanity conference call to discuss the top line results of the Phase Ib clinical trial of YTX-7739. (Operator Instructions) Please note that this call is being recorded.
It is now my pleasure to turn the call over to Lee Roth, Senior Vice President of Investor Relations at Burns McClellan. Please go ahead.
Thank you, Summer. Good morning, everyone, and once again, welcome to Yumanity's conference call to discuss the top line results of the Phase Ib clinical trial of YTX-7739. We issued a press release earlier this morning outlining these results, which can be accessed on the investors portion of our website at yumanity.com.
Joining me on the call today are Richard Peters, Chief Executive Officer of Yumanity; Ajay Verma, EVP, Head of Research and Development; Michael Wyzga, Chief Financial Officer; and Paulash Mohsen, Chief Business Officer.
Before we begin, I'd like to remind you that today's discussion will include statements about our future
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |